Topical Tamoxifen in DCIS - Clinical Trial
What is the Purpose of this Study?
We are doing this study to test the use of a topical Tamoxifen gel prior to surgery to see if it will decrease the growth rate of DCIS cells.
Ductal Carcinoma In Situ (DCIS)
Who Can Participate in the Study?
- Are diagnosed with ER positive DCIS of the breast
- Are at increased risk for future invasive breast cancer
What is Involved?
If you choose to join this study, you will:
- Be randomized (like the flip of a coin) to one of the two treatment groups:
-- Group 1 will get a topical Tamoxifen gel to use once a day for 4-10 weeks prior to surgery plus a placebo (inactive medicine) capsule taken every day
-- Group 2 will get the placebo (inactive medicine) gel to use once a day for 4-10 weeks prior to surgery plus a Tamoxifen capsule to take every day